Oramed Pharmaceuticals Inc. (ORMP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Oramed Pharmaceuticals Inc. (ORMP) Healthcare & Pipeline Overview

Oramed Pharmaceuticals Inc. pioneers oral drug delivery, focusing on diabetes treatments with its lead product ORMD-0801, an oral insulin capsule in clinical trials. The company aims to transform peptide and protein delivery, addressing a significant unmet need in the diabetes market and positioning itself within the biotechnology sector.

What Is the Investment Thesis for ORMP?

Oramed Pharmaceuticals Inc. presents a notable research candidate due to its innovative approach to oral drug delivery, particularly in the diabetes market. The successful development and commercialization of ORMD-0801, its oral insulin capsule, could revolutionize diabetes treatment and capture a significant share of the insulin market. Key value drivers include positive clinical trial results, strategic partnerships, and regulatory approvals. The company's high profit margin of 3766.2% suggests strong potential profitability if its products reach the market. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established diabetes treatments. The company's dividend yield of 6.11% may attract income-seeking investors. The company's beta of 1.25 indicates higher volatility compared to the market.

Based on FMP financials and quantitative analysis

ORMP Key Highlights

Market capitalization of $194M reflects investor valuation of Oramed's potential in the oral drug delivery market.

• P/E ratio of 1.13 indicates the stock may be undervalued compared to its earnings.
• Profit margin of 3766.2% suggests high potential profitability if Oramed's products are successfully commercialized.
• Gross margin of 0.7% indicates the percentage of revenue exceeding the cost of goods sold.
• Dividend yield of 6.11% provides an income stream for investors, potentially attracting those seeking regular returns.

Who Are ORMP's Competitors?

ORMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ORMP's Key Strengths?

Innovative oral drug delivery technology.

• Proprietary oral insulin formulation.
• Potential to disrupt the diabetes treatment market.
• Experienced management team.

What Are ORMP's Weaknesses?

Limited financial resources.

• Dependence on successful clinical trial outcomes.
• Regulatory hurdles and approval timelines.
• Competition from established pharmaceutical companies.

What Could Drive ORMP Stock Higher?

Announcement of Phase III clinical trial results for ORMD-0801.

• Potential regulatory approval of ORMD-0801 by the FDA or other regulatory agencies.
• Progress in the development of ORMD-0901 and other pipeline products.
• Strategic partnerships with pharmaceutical companies.
• Expansion into new markets.

What Are the Key Risks for ORMP?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Insider selling — insiders were net sellers of roughly $2.5M recently.
• Failure to achieve positive results in Phase III clinical trials for ORMD-0801.
• Regulatory delays or rejection of ORMD-0801.
• Competition from established diabetes treatments.
• Dependence on securing additional funding to support research and development.
• Patent challenges or infringement.

What Are the Growth Opportunities for ORMP?

• Successful completion of Phase III clinical trials for ORMD-0801 represents a significant growth opportunity. Positive results would pave the way for regulatory approval and commercialization, potentially capturing a substantial share of the oral insulin market. The global insulin market is projected to reach $25 billion by 2028, offering a large addressable market for Oramed. Timeline: Anticipated completion of Phase III trials by 2027.
• Expansion of the product pipeline to include additional oral drug delivery systems for other therapeutic areas beyond diabetes. This could involve developing oral formulations for other polypeptides or proteins that are currently administered via injection. The market for oral biologics is estimated to reach $10 billion by 2030, presenting a significant growth opportunity for Oramed. Timeline: Ongoing research and development efforts with potential new product launches by 2028.
• Strategic partnerships with pharmaceutical companies to co-develop and commercialize Oramed's oral drug delivery technologies. Collaborations could provide access to additional funding, expertise, and distribution channels, accelerating the commercialization of Oramed's products. The pharmaceutical industry is increasingly seeking innovative drug delivery technologies, creating opportunities for partnerships. Timeline: Potential partnership announcements within the next 1-2 years.
• Geographic expansion into new markets, particularly in developing countries where access to injectable insulin may be limited. Oral insulin could offer a more convenient and affordable treatment option for patients in these regions. The diabetes market in developing countries is growing rapidly, driven by rising rates of obesity and urbanization. Timeline: Potential expansion into select developing markets by 2029.
• Development of personalized medicine approaches using Oramed's oral drug delivery platform. This could involve tailoring drug dosages and formulations to individual patient needs, improving treatment outcomes and reducing side effects. Timeline: Long-term research and development efforts with potential personalized medicine applications by 2030.

What Are ORMP's Competitive Advantages?

• Proprietary oral drug delivery technology.
• Patents protecting their oral insulin formulation.
• Clinical trial data demonstrating the efficacy of their products.
• First-mover advantage in the oral insulin market.

What Does ORMP Do?

Oramed Pharmaceuticals Inc., founded in 2002 and headquartered in New York City, is a pharmaceutical company dedicated to the research and development of innovative drug delivery systems. The company's primary focus is on creating orally ingestible capsules for the delivery of polypeptides, addressing the limitations of traditional injectable treatments. Oramed's flagship product, ORMD-0801, is an orally ingestible insulin capsule designed for the treatment of diabetes. This product has completed Phase II clinical trials and represents a potential breakthrough in diabetes management by offering a more convenient and patient-friendly alternative to insulin injections. In addition to ORMD-0801, Oramed is also developing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule for the treatment of type 2 diabetes, which has completed Phase I clinical trials. The company is also exploring a weight loss treatment in the form of an oral leptin capsule. Oramed's technology aims to improve drug efficacy, reduce side effects, and enhance patient compliance by enabling oral delivery of drugs that are typically administered through injections. Formerly known as Integrated Security Technologies, Inc., the company rebranded as Oramed Pharmaceuticals Inc. in April 2006 to reflect its focus on pharmaceutical innovation.

What Products and Services Does ORMP Offer?

• Develop orally ingestible capsules for polypeptide delivery.
• Research pharmaceutical solutions for diabetes treatment.
• Focus on oral delivery of insulin as an alternative to injections.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Seek regulatory approval for their products from agencies like the FDA.
• Explore partnerships with pharmaceutical companies for co-development and commercialization.

How Does ORMP Make Money?

• Develop and patent oral drug delivery technologies.
• Conduct clinical trials to demonstrate the safety and efficacy of their products.
• Seek regulatory approval for their products.
• Commercialize their products through partnerships or direct sales.

What Industry Does ORMP Operate In?

Oramed Pharmaceuticals Inc. operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The diabetes market, in particular, is a large and growing market driven by the increasing prevalence of diabetes worldwide. Oramed's focus on oral insulin delivery positions it within a niche segment of the diabetes market, targeting patients who prefer oral medications over injections. The company faces competition from established pharmaceutical companies that produce injectable insulin and other diabetes treatments. The biotechnology industry is subject to strict regulatory oversight by agencies such as the FDA, requiring companies to conduct extensive clinical trials to demonstrate the safety and efficacy of their products.

Who Are ORMP's Key Customers?

• Patients with diabetes who require insulin therapy.
• Pharmaceutical companies seeking innovative drug delivery technologies.
• Healthcare providers who prescribe diabetes treatments.

Company Profile

Oramed Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Nadav Kidron. ORMP has traded publicly since 2007.

How Oramed Pharmaceuticals Inc. Is Valued

Oramed Pharmaceuticals Inc. carries a market capitalization of $194M, placing it in the micro-cap category. Relative to its peer group, ORMP's quantitative score of 78/100 is roughly in line with the peer average of 79/100.

Return on equity for Oramed Pharmaceuticals Inc. stands at 55.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 40.9%, showing how much profit it generates from its asset base. ORMP trades at a trailing price-to-earnings ratio of 1.13, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 59.2%, the inverse of the P/E and a quick read on earnings relative to price.

Oramed Pharmaceuticals Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.80 places it in the safe zone, indicating low near-term bankruptcy risk.

Oramed Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 516.1% below estimates on average.

Wall Street analysts project Oramed Pharmaceuticals Inc. revenue of about $1.2M for fiscal 2026, with EPS near $4.47.

Over the past six months, Oramed Pharmaceuticals Inc. insiders filed 10 SEC Form 4 transactions — 5 sales and 5 purchases. On net that is roughly 212K shares disposed (about $2.5M), a signal worth weighing alongside the fundamentals.

ORMP Financials

ORMP Latest News

ORMP Analyst Consensus

ORMP MoonshotScore

ORMP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources